Starting Dose for Dapagliflozin in Heart Failure
The starting dose of dapagliflozin for heart failure is 10 mg orally once daily, regardless of whether the patient has reduced or preserved ejection fraction, provided the eGFR is ≥25 mL/min/1.73 m² 1.
Dosing by Indication and Renal Function
For Heart Failure (HFrEF or HFpEF)
- Standard dose: 10 mg once daily 1
- This applies to both heart failure with reduced ejection fraction (HFrEF) and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) 2
- No dose titration is needed—unlike glycemic control where you might start at 5 mg, heart failure treatment begins and stays at 10 mg 1
Renal Function Considerations
- eGFR ≥25 mL/min/1.73 m²: Use standard 10 mg dose 1
- eGFR <25 mL/min/1.73 m²: Initiation is NOT recommended 1
- If eGFR falls below 25 after starting: Continue 10 mg daily for cardiovascular and kidney benefits 1, 3
- Contraindicated in dialysis patients 1
Key Distinction from Diabetes Dosing
This is critically important: The heart failure dose differs from the diabetes dose. For glycemic control in type 2 diabetes, you start at 5 mg and may increase to 10 mg 1. However, for heart failure indications, you start directly at 10 mg and do not titrate 1.
Pre-Initiation Assessment
Before starting dapagliflozin 1:
- Check eGFR to confirm ≥25 mL/min/1.73 m²
- Assess volume status—correct volume depletion before initiating to reduce hypotension risk
- Consider temporarily holding during acute illness or before major surgery (withhold ≥3 days if possible) 1
Expected Initial eGFR Decline
An initial dip in eGFR is expected and not a reason to discontinue:
- Average decline of 3-4 mL/min/1.73 m² in the first 2 weeks 4, 5
- Approximately 38-40% of patients experience >10% eGFR decline initially 4, 5
- This initial decline is hemodynamic, not indicative of kidney injury, and is associated with better long-term outcomes 4, 6
- Do not stop or reduce the dose in response to this expected initial decline 5
Clinical Trial Evidence
The 10 mg dose was used consistently across major heart failure trials:
- DAPA-HF (HFrEF): 10 mg daily, eGFR ≥30 required 7
- DELIVER (HFmrEF/HFpEF): 10 mg daily, eGFR ≥25 required 8
- Both trials demonstrated significant reductions in cardiovascular death and heart failure hospitalizations 9
Common Pitfall to Avoid
Do not start at 5 mg for heart failure patients. The 5 mg dose is only for initiating glycemic control in diabetes 1. For heart failure, cardiovascular risk reduction, or chronic kidney disease indications, the dose is always 10 mg from day one 2, 1.